# A Study to Evaluate the Relative Bioavailability and Tolerability of Bimekizumab in Healthy Subjects

> **NCT05028127** · PHASE1 · COMPLETED · sponsor: **UCB Celltech** · enrollment: 12 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Bimekizumab

## Key facts

- **NCT ID:** NCT05028127
- **Lead sponsor:** UCB Celltech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-04
- **Primary completion:** 2016-06-17
- **Final completion:** 2016-06-17
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2021-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05028127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05028127, "A Study to Evaluate the Relative Bioavailability and Tolerability of Bimekizumab in Healthy Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05028127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*